Bausch Health Companies Inc.
NYSE · us_market
No AI summary generated yet for this ticker.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May 28, 2026
Oligometastatic Disease (OMD) is a cancer stage where the disease spreads to a limited number of sites, offering a better prognosis than widespread metastasis. The OMD market is experiencing growth, driven by advances in diagnostic technologies like MRI and PET scans, and innovative treatments such as targeted therapies and immunotherapy. North America leads the market due to advanced healthcare systems, while Asia-Pacific, Latin America, and Africa offer growth opportunities. Challenges include
Bausch Health Companies Inc. (BHC) RBC Capital Markets Global Healthcare Conference 2026 May 20, 2026 9:30 AM EDTCompany ParticipantsThomas Appio - CEO...
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc
Bausch Health Companies Inc. (BHC) Barclays 30th Annual Leveraged Finance Conference 2026 May 19, 2026 10:25 AM EDTCompany ParticipantsWilliam Woodfield -...
The cannabis pharmaceuticals market is poised for significant growth due to rising medical cannabis legalization, increasing R&D investment, and demand for alternative treatments. Key opportunities include advancements in cannabinoid research, therapeutic applications in chronic pain, neurological disorders, and mental health conditions, and the development of cannabis-based formulations driven by regulatory approvals and evolving healthcare systems. Cannabis Pharmaceuticals Market Cannabis Phar
- 13F Filing
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2026 Global Healthcare Conference in New York City on Wednesday, May 20, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference in Austin, Texas on Tuesday, May 19, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.
Bausch Health delivered a Q1 revenue and net profit beat, but organic growth remains weak and demand is stagnant. Find out why BHC stock is a buy.
2026-05-04. The following slide deck was published by Bausch Health Companies Inc.
Investors liked what they saw with the company's opening 2026 earnings report.
Investors liked what they saw with the company's opening 2026 earnings report.
The Toronto Stock Exchange is up 455 points at midday, partially recouping some of the 630 points lo
The Toronto Stock Exchange is up 455 points at midday, partially recouping some of the 630 points lo
Bausch Health posts mixed Q1: EPS misses, but revenues beat estimates on strong Salix and Solta growth. Pipeline progress and the raised 2026 view add momentum.
Bausch Health posts mixed Q1: EPS misses, but revenues beat estimates on strong Salix and Solta growth. Pipeline progress and the raised 2026 view add momentum.
Moby summary of Bausch Health Companies Inc.'s Q1 2026 earnings call
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-29upcoming | 1.00 | — | — |
| 2026-04-29 | 0.69 | 0.78 | +12.81% |
| 2026-02-18 | 1.26 | 1.10 | -12.85% |
| 2025-10-29 | 1.06 | 1.16 | +10.00% |
| 2025-07-30 | 0.05 | 0.40 | +788.89% |
| 2025-04-30 | 0.85 | 0.61 | -28.26% |
| 2025-02-19 | 1.13 | 1.16 | +2.96% |
| 2024-10-30 | 1.02 | 1.12 | +9.63% |
| 2024-08-01 | 0.88 | 0.98 | +12.24% |
| 2024-05-02 | 0.72 | 0.59 | -17.83% |
| 2024-02-22 | 1.02 | 1.17 | +14.75% |
| 2023-11-02 | 0.92 | 1.03 | +12.04% |
| 2023-08-03 | 0.73 | 0.81 | +10.26% |
| 2023-05-04 | 0.68 | 0.53 | -21.96% |
| 2023-02-23 | 0.95 | 1.03 | +8.31% |
| 2022-11-03 | 0.78 | 0.76 | -2.09% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BHC | -5.13% | -6.46% | -22.88% | +18.32% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -8.10% | -1.82% | -19.43% | +5.63% |